Achmea Investment Management B.V. grew its stake in shares of Royalty Pharma plc () by 3,888.8% during the third quarter, reports.

Source: https://www.etfdailynews.com/2023/01/09/achmea-investment-management-b-v-buys-19094-shares-of-royalty-pharma-plc-nasdaqrprx/

Captrust Financial Advisors increased its position in Royalty Pharma by 210.8% during the second quarter.

Source: https://www.etfdailynews.com/2023/04/08/royalty-pharma-nasdaqrprx-pt-raised-to-60-00/

Finally, ASB Consultores LLC grew its position in Royalty Pharma by 38.7% during the fourth quarter.

Source: https://www.americanbankingnews.com/2023/06/13/alyeska-investment-group-l-p-invests-20-28-million-in-royalty-pharma-plc-nasdaqrprx.html

Finally, State Street Corp boosted its holdings in Royalty Pharma by 9.7% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/02/22/bank-of-montreal-can-boosts-stock-position-in-royalty-pharma-plc-nasdaqrprx/

Five analysts have rated the stock with a buy rating, According to MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and an average price target of $54.

Source: https://www.dailypolitical.com/2023/05/26/royalty-pharma-nasdaqrprx-raised-to-buy-at-stocknews-com.html

In January, Ionis announced it had sold an interest in two of its medicines to Royalty Pharma for $500 million upfront and up to $625 million in additional payments based on future production.

Source: https://www.sandiegouniontribune.com/communities/north-county/carlsbad/story/2023-03-05/ionis-pharmaceuticals-plans-large-expansion-in-carlsbad

In other Royalty Pharma news, EVP George W. Lloyd sold 100,000 shares of the stock in a transaction dated Tuesday, March 28th.

Source: https://www.etfdailynews.com/2023/05/28/first-trust-advisors-lp-decreases-stock-holdings-in-royalty-pharma-plc-nasdaqrprx/

JPMorgan Chase & Co. raised their price objective on shares of Royalty Pharma from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 18th.

Source: https://www.etfdailynews.com/2023/02/13/allianz-asset-management-gmbh-boosts-holdings-in-royalty-pharma-plc-nasdaqrprx/

Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies.

Source: https://www.marketscreener.com/quote/stock/ROYALTY-PHARMA-PLC-108435084/news/Royalty-Pharma-Announces-1-0-Billion-Share-Repurchase-Program-43346974/?utm_medium=RSS&utm_content=20230327

Royalty Pharma plc has a 52 week low of $32.68 and a 52 week high of $44.66.

Source: https://www.etfdailynews.com/2023/05/01/asset-management-one-co-ltd-has-5-29-million-stock-position-in-royalty-pharma-plc-nasdaqrprx/